SCHEMBL10173395

SCHEMBL10173395

CCCNC(=O)C1=CCCN1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.40
POLB P06746 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
THRB P10828 1/20 0.40
RECQL P46063 1/20 0.40
CHRNB2 P17787 1/20 0.39
CHRNA4 P43681 1/20 0.39
CHRNA10 Q9GZZ6 1/20 0.39
CHRNA9 Q9UGM1 1/20 0.39
PKM P14618 1/20 0.36
KMT2A Q03164 3/20 0.36
KDM4E B2RXH2 3/20 0.36
HSD17B10 Q99714 1/20 0.36
GLA P06280 1/20 0.36
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MEN1 O00255 1/20 0.35
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
MMP3 P08254 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14218147 0.86 CHRNB2 (0.41) THRBCHRNB2CHRNA4KMT2ASMN1; SMN2
SCHEMBL8404353 0.74 CHRNB2 (0.55) THRBCHRNB2CHRNA4KMT2AHPGD
SCHEMBL13182376 0.70
SCHEMBL12283650 0.70
SCHEMBL13185234 0.69 POLB (0.45) L3MBTL1POLBTDP1THRBRECQL
SCHEMBL6127902 0.66 ALDH1A1 (0.43) KMT2AKDM4EALDH1A1
SCHEMBL13947189 0.66 CHRNB2 (0.37) THRBCHRNB2CHRNA4
SCHEMBL4572657 0.66 CHRNB2 (0.38) L3MBTL1TDP1THRBRECQLCHRNB2
SCHEMBL25799690 0.65 NPSR1 (0.46) POLBTDP1KMT2AMEN1
SCHEMBL13918749 0.64 KDM4E (0.70) L3MBTL1POLBCHRNA10CHRNA9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8168654-B2 Quinuclidine derivatives binding to mucarinic M3 receptors NOVARTIS AG (CH) 2012-05-01 US disclosed
US-20100041887-A1 QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS COLLINGWOOD STEPHEN PAUL 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041887-A1 QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS CHRM3, CHRM2, CHRM1 L3MBTL1 3806/4885POLB 4046/4885TDP1 4090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.